Claims for Patent: 9,687,517

Summary for Patent: 9,687,517

Title:	Methods and compositions for treating skin
Abstract:	A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
Inventor(s):	Collins; Donald F. (Plainview, NY), Maes; Daniel H. (Huntington, NY), Muizzuddin; Neelam (Bethpage, NY)
Assignee:	ELC Management LLC (New York, NY)
Application Number:	14/079,929
Patent Claims:	1. A method for treating intact irritated or inflamed skin by topically applying a composition in the form of anhydrous, emulsion, or gel composition that comprises from 0.001 to 20% by weight of the total composition of each of (a) through (f): (a) at least one Histamine pathway inhibitor selected from the group consisting of apigenin; flavones; celery extract; parsley extract; citrus fruit extracts; amentoflavones; luteolin, flavinoids; phloretins, or 2',4',6',4-Tetrahydroxydihydrochalcones; grapeseed extract, Rosmarinus Officinalis extract, or mixtures thereof; (b) at least one Chemotaxis pathway inhibitor selected from the group consisting of licorice extract; genestein; extracts from the genus Scutellaria; extracts from the Boswellia genus; extract from the Commiphora genus; Bursera Microphylla extract; Nidularium Proceru extract; sequoia extract; hypoestoxide; Curcuma Longa (turmeric) extract; butyloctyl salicylate; abyssine; plai oil; geranium bourbon oil; jiagolun EX; fucoidan YSK; caffeine; galactoarabinan; lion's mane mushroom extract; clerilys extract; extracts from Macrycystis Pyrifera; reishi mushroom extract; Pleurotus Ostreatus extract; Hypsizygus Ulmarius extract; Cladosiphon Okamuranus Extract; Acalypha Wilkesiana extract; Acanthopanax Gracilistylus extract; Allium Sativum extract; Ananus Comosus extract; Cissampelos Sympodialis extract; Coriolus Versicolor extract; Echinacea Purpurea extract; Grifola Frondosa extract; Harpagophytum Procumbens extract; Panax Ginseng extract; Polygala Tenuifolia extract; Poria Cocos extract; Silybum Marianum extract; Smilax Glabra extract; Tinospora Cordifolia extract; Uncaria Tomentosa extract; Withania Somnifera extract; slime mold; Echinancea extract; Viscum Album extract; coffee robusta seed extract; capsaicin; a hexapeptide having the amino acid sequence (SEQ ID NO: 1) Val-Gly-Val-Ala-Pro-Gly (VGVAPG); ubiquitin; nicotinalides; cytochalasin B; and mixtures thereof; (c) at least one Adhesion pathway inhibitor selected from the group consisting of algae extract, neem oil limonoids, Asparagus Racemusus extract, Platycodon extract, Chaga Mushroom extract, Emblica Officinalis extract, Criste Marine extract, Lavande Papillon extract, Polygonum Cuspidatum, ginger, and mixtures thereof; (d) at least one Elastase pathway inhibitor selected from the group consisting of Boswellia Serratia extract, winter begonia extract, oleanolic acid, ursolic acid, phytocohesin, Pygeum Africanum extract, Padina Pavonica extract, Actina Boswellia extract, ligustrum, dipalmitoyl hydroxyproline, Soft Pygeurm extract, chaga mushroom, 7-dehydrocholesterol, white birch extract, polyphenon E, jojoba protein isolate, red raspberry powder, heather extract, hesperitin, hibiscin, mixture of soybean protein and oxido reductases, grapeseed extract, a mixture of butcher's broom extract and heperidin methyl chalcone, hesperidin, caffeine, a protein hydrolysate obtained from extracted organic germinated wheat seeds, hesperitin, glycine soja protein, jojoba oil, Olea Europaea fruit extract, and mixtures thereof; (e) at least one Collagenase pathway inhibitor selected from the group consisting of extracts from the Siegesbeckia genus; Siegesbeckia Orientalis; extracts from the Doliocarpus genus; Doliocarpus Verruculosus; extracts from the Kaempferia genus; Kaempferia galanga root extract; extracts from the Camilla genus; Camilla Sinensis; extracts from the Sauropus genus; Sauropus androgvnus; extracts from the Tetracapidium genus; Tetracapidium conophorum; glucosamine; N-acetyl glucoseamine; chondroitan sulfate; Pinus Pinaster (pine bark) extract; lysine; Vitis Vinefera (grape) seed extract; retinoids retinyl palmitate; retinol; retinoic acid; extracts from the Pluchea genus; Pluchea Indica (Compositae); extracts from the Viola genus; Viola hondoensis; cocoa bean; extracts from the Triphala genus; Triphala Chebula; anthocyanins; epigallocatechingallate; epicatechingallate; luteolin; Citri Reticulatae peel extract; winter begonia extract; extracts from the Tepescohuite genus; extracts from the Mimosa genus; Mimosa Pudica extract; picolinic acid; Silymarin extracts; Eucommia extracts; amentoflavone; extracts from the Menyanthes genus; Menyanthes Trifoliate extract; and mixtures thereof; and (f) at least one Phosphodiesterase pathway inhibitor selected from the group consisting of nordihydroguaiaretic acid; emodin; 18-B-glycerrhetinic acid; caffeine; wild yam powder; Anemarrhena asphodeloides; Zhi Mu extract; Eucomia extract; Uncaria tomentosa; and mixtures thereof; wherein said composition does not contain hydrocortisone and the combination of (a) through (f) provide the composition with an efficacy in inhibiting irritation or inflammation in skin that is equal to or greater than the efficacy of a composition containing 1% hydrocortisone. 2. The method of claim 1 wherein the Histamine pathway inhibitor comprises a citrus fruit extract which is grapefruit extract. 3. The method of claim 1 wherein the Histamine pathway inhibitor is grapefruit peel extract. 4. The method of claim 1 wherein the Chemotaxis pathway inhibitor is selected from the group consisting of licorice extract; extracts from the genus Scutellaria; Cladosiphon Okamuranus Extract; and mixtures thereof. 5. The method of claim 1 wherein the Adhesion pathway inhibitor is algae extract. 6. The method of claim 1 wherein the Elastase pathway inhibitor selected from the group consisting of germinated wheat seeds, glycine soja protein, jojoba oil, and mixtures thereof. 7. The method of claim 1 wherein the Collagenase inhibitor is selected from the group consisting of extracts from the Siegesheckia genus; Vitis Vinefera (grape) seed extract; and mixtures thereof. 8. The method of claim 1 wherein the Phosphodiesterase pathway inhibitor is caffeine. 9. The method of claim 1 wherein the composition is tested for by applying to a 1.5 inch square of the volar forearm and after 20 minutes 4 mg/cm.sup.2 Balsam of Peru is applied in a 1.5 cm diameter circle to the site where the composition was applied and the degree of redness is measured with a chromameter. 10. A method for treating intact irritated or inflamed skin for redness, pain or heat by topically applying to the skin a composition in the form of anhydrous, emulsion, or gel composition comprising from 0.001 to 20% by weight of the total composition of each of (a) through (f): (a)--at least one Histamine pathway inhibitor; (b)--at least one Chemotaxis pathway inhibitor, (c)--at least one Elastase pathway inhibitor, (d)--at least one Collagenase pathway inhibitor; (e)--at least one Phosphodiesterase pathway inhibitor; and (f)--at least one Adhesion pathway inhibitor; wherein said composition does not contain hydrocortisone and the combination of (a) through (f) provide the composition with an efficacy in inhibiting irritation or inflammation in skin that is equal to or greater than the efficacy of a composition containing 1% hydrocortisone. 11. The method of claim 10 wherein the Histamine pathway inhibitor is grapefruit peel extract; the Chemotaxis pathway inhibitor is Scutellaria baicalensis extract, glycyrrhetinic acid, Cladosiphon okamuranus extract or mixtures thereof; the Elastase pathway inhibitor is wheat germ extract, soybean protein, or mixtures thereof; the Collagenase pathway inhibitor is Vitis vinefera extract, Siegesbeckia orientalis, acetyl glucosamine or mixtures thereof; the Phosphodiesterase pathway inhibitor is caffeine; and the Adhesion pathway inhibitor is Algae extract. 12. The method of claim 11 wherein the emulsion is in the form of a skin care cream, lotion, or serum. 13. The method of claim 10 wherein the composition additionally comprises one or more of the following: a Phospholipase A2 pathway inhibitor; a Vascular Endothelial Growth Factor pathway inhibitor; a COX pathway inhibitor; a Histamine Receptor pathway inhibitor; or a Lipoxygenase pathway inhibitor.

Details for Patent 9,687,517

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2027-12-20
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2027-12-20